AI Terminal
Saniona
Interim / Quarterly Report • Aug 28, 2025
3195_ir_2025-08-28_0c7751fb-2ca7-4859-9913-8d526e922ce1.pdf
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
Saniona has entered its next phase of growth, with two landmark partnerships in less than a year and a strong financial foundation
| Three Months Ended June 30, 2025 (2024) | Six Months Ended June 30, 2025 (2024) |
|---|---|
| Revenue was SEK 9.3 M (8.0 M) | Revenue was SEK 19.1 M (14.1 M) |
| Operating profit/loss was SEK -25.9 M (-16.0 M) | Operating profit/loss was SEK -42.4 M (-29.7 M) |
| Net profit/loss was SEK -22.2 M (-19.7 M) | Net profit/loss was SEK -3.3 M (-29.0 M) |
| Cash and cash equivalent SEK 308.2 M (54.4) | Cash and cash equivalent SEK 308.2 M (54.4) |
| Basic earnings/loss per share was SEK -0.17 (-0.18) | Basic earnings/loss per share was SEK -0.03 (-0.29) |
| Diluted earnings/loss per share were SEK -0.17 (-0.18) | Diluted earnings/loss per share were SEK -0.03 (-0.29) |
Business highlights in Q2 2025
- On April 3, Saniona announced the final outcome of exercise of warrants series TO 4, corresponding to a total of SEK 111.3 million after issue costs, which corresponds to 100 percent of the total number of TO 4 warrants.
- On May 12, Saniona appointed Johnny Stilou as Chief Financial Officer.
- On June 19, Saniona acquires headquarters to secure long-term stability, funded from existing cash reserves of SEK 72.2 million (DKK 49 million). On July 1, Saniona took over the ownership of the headquarters.
- On June 26, Fenja Capital II A/S requested a conversion of the remaining outstanding convertibles for a total nominal amount of SEK 6 million, whereby a total of 1,941,747 new shares were issued. The issue of the new shares to Fenja Capital II A/S took place in July 2025.
Significant events after the reporting period
• On August 20, Saniona announced Licensing Agreement with Jazz Pharmaceuticals for SAN2355 in epilepsy and other potential indications. Saniona will receive an upfront payment of USD 42.5 million.
Comments from the CEO
"Saniona has entered its next phase of growth. With two landmark partnerships in less than a year and a strong financial foundation, we are advancing our focused pipeline of innovative medicines toward key clinical milestones. The collaboration with Jazz Pharmaceuticals validates our R&D approach, secures progress of SAN2355, and provides the resources to independently advance SAN2219, SAN2465 and other internal programs into Phase 2. We are building a company with the potential to deliver transformative therapies in neurology and psychiatry while creating long-term value for our shareholders."
For more information, please contact
Johnny Stilou, CFO, +45 21 227 227; [email protected]
Forward-looking statements
The report contains certain forward-looking information that reflects Saniona's current views of future events and financial and operational performance. Words such as "intends", "anticipates", "expects", "can", "plans", "estimates" and similar expressions regarding indications or forecasts of future developments or trends, and which are not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it is dependent on future events and circumstances. Forward-looking information is not a guarantee of future results or developments and actual results may differ materially from results referred to in forward-looking information. Forwardlooking information in the report is only applicable on the date of issue of the report. Saniona does not commit to publishing updates or revision of any forward-looking statements as a result of new information, future events or similar circumstances other than those required by applicable legislation.
Letter from the CEO
Dear Shareholders,
During the second quarter of 2025, Saniona advanced its pipeline and strengthened its financial position through a new strategic partnership. This effort culminated in a significant licensing agreement with Jazz Pharmaceuticals for SAN2355 in August, underscoring the value of Saniona's innovative R&D and product pipeline.
The Jazz agreement is transformational for Saniona. It validates our R&D approach, secures the progress of one of our lead assets, and provides the financial strength to advance our internal clinical development efforts.
Strengthening Our Financial Foundation
At the beginning of the quarter, we completed the TO4 financing, raising approximately SEK 115 million before issue costs. This followed our November 2024 agreement with Acadia, which included a USD 28 million (SEK 300 million) upfront payment, potential future milestone payments of up to USD 582 million (SEK 6.2 billion), and tiered royalties on future sales. The next milestone payment of USD 10 million (SEK 107 million) is expected upon initiation of a Phase 2 clinical trial.
In August, we signed an exclusive worldwide license agreement with Jazz Pharmaceuticals for SAN2355, our highly selective Kv7.2/7.3 activator for the treatment of epilepsy. Saniona will receive USD 42.5 million (SEK 406 million) in upfront payment, as well as potential clinical, regulatory and commercial milestone payments of up to USD 992.5 million (SEK 9,5 billion), and tiered royalties on future net sales. The first milestone payment of USD 7.5 million (SEK 72 million) will be payable upon initiation of the Phase 1 clinical trial. Jazz will assume responsibility for all future development, regulatory submissions, and commercialization, while Saniona focuses on advancing its internal pipeline.
All future communication regarding the progress of SAN2355 will be at Jazz's discretion.
Within the past 10 months, Saniona has closed two of the largest transactions by listed biotech companies in Sweden. The agreement with Jazz is noteworthy as it directly builds on our internal research over the past three years: lead optimization in 2022, clinical candidate selection in 2023, and preclinical development in 2024.
Advancing Our Internal Pipeline
Proceeds from Acadia, Jazz, and the TO4 financing enable us to independently advance several internal development programs through Phase 2 clinical studies.
During the quarter, we progressed preclinical development for SAN2219 for epilepsy and SAN2465 for major depressive disorder, as well as our epilepsy research program AN2668, enabling us to accelerate development following potential candidate selection.
Phase 1 studies for all three programs will include biomarkers to confirm functional activity and guide dose selection for subsequent Phase 2 trials, which we expect to initiate in two to three years for SAN2219, SAN2465, and AN2668 if it is nominated as a clinical candidate.
Tesofensine
Our partner Medix submitted a complete regulatory dossier in Mexico in Q1. At that time, we were encouraged by the progress, though we noted that the approval timeline rests with the regulatory authorities, Cofepris. Since then, Medix has received additional requests from Cofepris and held several follow-up interactions with the agency. While these discussions are ongoing, we cannot predict the outcome or timing of a potential approval of tesofensine in Mexico.
Acquisition of Headquarters
In Q2, we acquired Saniona's headquarters to secure long-term operational stability. While our original plan was a saleand-leaseback later this year, the Jazz agreement allows us to postpone such a transaction. The property is located in a transforming district, making the investment financially attractive over time.
Executing on Strategy and Looking Ahead
We are building a focused pipeline in neurological and psychiatric diseases and using non-dilutive capital from collaborations to reach key inflection points. The Acadia and Jazz agreements have validated both our science and business model, and we are now positioned to advance several assets through Phase 2.
While we continue to pursue new partnerships, our current focus is progressing our internal programs into the clinic.
Thank you for your continued support and confidence in Saniona.
Sincerely,
Thomas Feldthus CEO
About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company's internal pipeline includes SAN2219 for epilepsy and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico and Argentina, where a market authorization application is currently under review. In addition, Saniona has two clinical-stage programs available for partnering: Tesomet™, ready to advance to Phase 2b trials in rare eating disorders, and SAN903, ready to enter Phase 1 trials in inflammatory bowel disease. Saniona's ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market. For more information, visit www.saniona.com.
Pipeline
SANIONA'S INTERNAL PIPELINE
Saniona's internal pipeline (marked in yellow in pipeline overview) comprises two preclinical candidates, SAN2219 and SAN2355, for epilepsy and a preclinical candidate, SAN2465, for major depressive disorders (MDD). In addition, Saniona has a mature GABA PAM research program positioned for epilepsy.
SAN2219
SAN2219 is a subtype-selective positive allosteric modulator (PAM) of GABAA α2-, α3-, and α5-containing receptors, designed to provide broad antiseizure activity by dampening excessive neuronal activation throughout the brain. SAN2219 is in preclinical development, and Saniona expects to finalize the CTA/IND-enabling package for the start of Phase 1 clinical trials in the first half of 2026.
SAN2219 has demonstrated potent efficacy in rodent models for focal onset seizures, generalized tonic-clonic seizures, and absence seizures. Unlike benzodiazepines, it does not enhance the activity of GABAA α1-containing receptors, which are associated with sedation, ataxia, and tolerance to anticonvulsant effects. This selectivity is expected to make SAN2219 highly effective for a variety of epilepsy indications, including acute repetitive seizures, without the limitations of benzodiazepines.
Acute repetitive seizures, or cluster seizures, are seizures that breaks through despite maintenance antiseizure medications. They occur in 10% to 50% of epilepsy patients, depending on the definition and study design and can, without prompt intervention, escalate into status epilepticus, a life-threatening emergency. Benzodiazepines are the current standard of care but are restricted in dose frequency due to adverse effects and concerns about tolerance development.
Saniona believes SAN2219 has the potential to address a critical unmet need by providing a non-sedating, effective treatment for acute repetitive seizures devoid of the dose restrictions imposed on benzodiazepines.
SAN2465
SAN2465 is a highly potent and selective negative allosteric modulator (NAM) of GABAA α5-containing receptors, offering a novel approach for treatment of major depression, distinct from conventional antidepressants, NMDA antagonists, and psychedelic investigational drugs. It exhibits unprecedented affinity for the GABAA α5 target and has the potential to be a first-in-class treatment for the rapid resolution of depression. SAN2465 is in preclinical development and Saniona expects to finalize the CTA/IND-enabling package for start of Phase 1 clinical trials in the second half of 2026.
Depressive disorders affect 280 million people worldwide and are the leading cause of disability. Current treatments, including selective serotonin reuptake inhibitors (SSRIs), often have delayed onset, low remission rates, and limited efficacy; more than 30% of patients do not respond adequately, leading to treatment-resistant depression. The FDA approved esketamine (Spravato™) in 2019 as the first fast-acting NMDA antagonist-based antidepressant. However, esketamine is associated with sedation, dissociation, respiratory depression, and abuse potential, requiring a Risk Evaluation and Mitigation Strategy (REMS) program.
There is a significant unmet need for safe, rapid-acting antidepressants without the use limitations of NMDA antagonists. SAN2465 has demonstrated efficacy in the chronic mild stress model of depression, a well-validated translational model. A single oral dose effectively reversed depressive-like symptoms within 24 hours, restoring sucrose intake, normalizing stress-induced anxiety and cognitive impairments, and showing an onset and robustness comparable to ketamine without observable adverse effects.
Unlike NMDA antagonists (e.g., esketamine) and psychedelics (e.g., psilocybin), SAN2465's mechanism does not predict sedation, dissociation, respiratory depression, hallucinations, or abuse potential. This differentiation suggests SAN2465 could offer a first-in-class, rapid-acting antidepressant without the significant safety concerns limiting current fast-acting therapies.
Beyond major depressive disorder, SAN2465 may also address neuropsychiatric symptoms in Dup15q syndrome, a rare genetic neurodevelopmental disorder with an estimated prevalence of 1 in 16,000. Characterized by intellectual disability, hypotonia, developmental delays, autism spectrum disorder, and refractory seizures, Dup15q currently has no FDA-approved treatments, providing potential for orphan drug designation.
Saniona's mature GABA program
Saniona has advanced additional compounds from its GABAA α2/α3 PAM program to the candidate selection phase. These compounds have distinct selectivity profiles from SAN2219.
The company is currently evaluating one candidate for the treatment of Developmental Epileptic Encephalopathy with Spike Wave Activation in Sleep (D/EE-SWAS), a rare pediatric epilepsy syndrome with high unmet need.
D/EE-SWAS affects an estimated 2,400 to 7,000 children in the U.S., typically emerging between ages 2 and 12. The syndrome is characterized by epilepsy and cognitive and developmental regression. It presents with a near-continuous activation of epileptiform activity specifically during non-rapid eye movement (NREM) sleep. Successful early treatment may improve cognitive and developmental outcome.
There is currently no approved treatment for D/EE-SWAS and no industry-sponsored clinical trials are currently ongoing. Patients are typically treated with traditional antiseizure medication including high dose benzodiazepines, steroids or brain surgery; all of which are associated with marked use limitations.
Sanionas GABA program is targeting the root cause of the seizure physiology and may therefore potentially prevent the neurocognitive- and developmental disabilities without the use limitations associated with high dose benzodiazepines and steroids. Accordingly, Sanionas GABA program offers the possibility for being the first approved treatment for this severe pediatric epileptic syndrome with a great unmet need.
SANIONA'S PARTNERED PROGRAMS
Saniona partnered programs include two strategic development collaborations and three research collaborations.
Strategic development collaborations are focused on advancing specific programs toward clinical development and commercialization.
Research collaborations aim to identify and develop novel drug candidates, with the potential to transition into full development programs.
SAN2355, Jazz Pharmaceutical
Saniona's partner Jazz is preparing SAN2355 for Phase 1 clinical studies. Jazz plans to develop SAN2355 for epilepsy. Jazz has exclusive worldwide rights to develop and commercialize SAN2355 in epilepsy and other potential indications. Jazz will lead and fund further development, regulatory submissions, and global commercialization activities.
Under the License Agreement entered in 2025, Saniona will receive a USD 42.5 million (SEK 406 million) upfront payment and is eligible for up to USD 992.5 million (SEK 9.5 billion) in milestone payments. The first milestone payment of USD 7.5 million (SEK 72 million) will be triggered upon initiation of the first Phase 1 study. Potential milestone payments include up to USD 192.5 million (SEK 1.8 billion) in development and regulatory milestones and up to USD 800 million (SEK 7.6 billion) in commercial milestones. Saniona is also entitled to tiered royalties ranging from mid-single digits to low-double digits on net sales of commercial products resulting from the development of SAN2355.
SAN2355 is a preclinical, selective small molecule activator of Kv7.2/Kv7.3 potassium channels, a mechanism validated for seizure suppression. Prior Kv7-targeting agents have demonstrated clinical efficacy, but dosing appears to be limited by adverse events associated with off-target activation. SAN2355 is uniquely selective for Kv7.2/Kv7.3, the Kv7-subtypes responsible for seizure suppression, and avoids activation of other Kv7-subtypes. This selectivity enables SAN2355 to deliver dosing to optimal efficacy and supports its potential as a best-in-class treatment for epilepsy.
ACP-711, Acadia Pharmaceutical
Saniona and its partner Acadia are preparing ACP-711 for Phase 2 clinical studies. Acadia plans to develop ACP-711 for essential tremor, a neurological disorder characterized by involuntary shaking or trembling movements. A Phase 2 study is expected to begin in 2026. Acadia will lead and finance clinical development, regulatory submissions, and global commercialization, while Saniona oversees the Phase 1 study and supports Phase 2 preparation, which is fully funded by Acadia.
Under the License Agreement entered in 2024, Saniona received a USD 28 million (SEK 300 million) upfront payment and is eligible for up to USD 582 million (SEK 6.2 billion) in milestone payments. The first milestone payment of USD 10 million (SEK 107 million) will be triggered upon initiation of the first Phase 2 study. Potential milestone payments include up to USD 147 million (SEK 1.6 billion) for development and regulatory milestones across the first and second indications and up to USD 435 million (SEK 4.6 billion) based on sales thresholds. Saniona is also entitled to tiered royalties ranging from mid-single digits to low-double digits on net sales.
ACP-711 is a Positive Allosteric Modulator (PAM) of GABAA α3-containing receptors. GABA is a neurotransmitter that mediates inhibitory signals in the brain. Unlike benzodiazepines, which act on multiple GABAA subunits and are associated with sedation, motor instability, abuse potential, and memory impairment, ACP-711 selectively targets GABAA α3, potentially offering a more tolerable treatment option without these limitations.
Tesofensine, Productos Medix
Saniona's partner Medix has completed a successful Phase 3 study and submitted a new drug application to COFEPRIS, the Mexican food and drug administration, for tesofensine as a treatment for obesity. In February 2023, COFEPRIS' technical committee issued a favorable non-binding opinion on tesofensine, marking a key step in the regulatory review process. Medix holds exclusive commercialization rights in Mexico and Argentina, while Saniona is entitled to milestone payments and royalties.
Saniona retains commercial rights in the rest of the world and has the exclusive rights to utilize data from the Phase 3 trial in this territory.
Tesofensine is a monoamine reuptake inhibitor that increases levels of dopamine, serotonin, and noradrenaline neurotransmitters involved in appetite regulation, food-seeking behavior, and metabolism. Its weight-reducing effect was demonstrated in the six-month Phase 2 TIPO-1 trial, where patients receiving 0.50 mg per day achieved weight loss of 10% or more in 24 weeks - comparable to leading GLP-1 analogs. Unlike GLP-1 analogs, tesofensine is an oral tablet and does not require titration.
Medix's Phase 3 study was a 24-week, randomized, double-blind, placebo-controlled trial assessing two doses of tesofensine (0.25 mg and 0.50 mg) in 372 patients with obesity on diet and exercise. The primary endpoint was the average percentage and absolute weight loss compared to placebo, with secondary endpoints evaluating the proportion of patients achieving at least 5% and 10% weight loss.
The study confirmed Tesofensine's strong efficacy and favorable safety profile. At the 0.50 mg dose, patients achieved approximately 10% weight loss, with more than half losing over 10% of their body weight. Statistically significant reductions in key obesity-related risk factors were also observed. Tesofensine was well tolerated, with a safety profile similar to placebo, a low incidence of adverse events, and no significant impact on blood pressure. A minor but statistically significant increase in heart rate was noted.
With data from more than 20 clinical trials and approximately 1,600 patients exposed to therapeutic doses for up to one year, tesofensine has a robust safety dataset supporting regulatory filings in Mexico and Argentina, and potentially in other markets.
Boehringer Ingelheim collaboration
Saniona and Boehringer Ingelheim entered the research collaboration and license agreement in 2020, aiming to discover new treatments for schizophrenia by targeting a CNS ion channel.
Under the agreement, Boehringer Ingelheim holds exclusive worldwide rights to research, develop, manufacture, and commercialize the therapeutics resulting from the collaboration. Saniona is eligible to receive up to €76.5 million in milestone payments, as well as royalties on worldwide net sales. Boehringer Ingelheim covers all internal and external costs incurred by Saniona under the research plan on fully loaded bases.
The program is currently in the lead optimization stage following the successful research milestone in October 2024.
AstronauTx collaboration
Saniona and AstronauTx entered the ongoing research collaboration and option agreement in 2023. The objective of the collaboration is to identify new treatments for Alzheimer's disease and other neurodegenerative conditions by modulating a novel, undisclosed ion channel target.
AstronauTx has an option to obtain exclusive worldwide rights to research, develop, manufacture, and commercialize therapeutics identified through the collaboration. Saniona will receive milestone payments of up to USD 102 million upon the achievement of certain research, development, and regulatory milestones. In addition, Saniona is entitled to commercial milestone payments of up to USD 75 million and tiered royalties on net sales of any potential products commercialized by AstronauTx as a result of this collaboration. AstronauTx covers all internal and external costs incurred by Saniona under the research plan on fully loaded bases.
Cephagenix collaboration
Cephagenix was established in 2020 by Professor Jes Olesen and Saniona to develop novel migraine treatments targeting mechanisms identified through Professor Olesen's research. The company's lead program focuses on identifying subtype-selective KATP channel inhibitors for migraine treatment. Cephagenix has identified highly selective inhibitors of the KATP channel subtype expressed in intracranial arteries, with first-generation compounds demonstrating efficacy in a relevant rodent migraine model.
In January 2025, Saniona announced that Cephagenix has secured an up to €9 million tranched seed financing from AdBio Partners and AbbVie Ventures. Saniona has the right but not the obligation to participate in certain future tranches at the same terms as the financial investors.
Cephagenix and Saniona also entered into a new research agreement in January 2025. Under the agreement Saniona has received success-based warrants to obtain additional shares in Cephagenix and is entitled to commercial milestone payments for potential products commercialized as a result of the collaboration. Cephagenix covers all internal and external costs incurred by Saniona under the research plan on fully loaded bases.
PROGRAMS POSITONED FOR PARTNERING
Tesomet™
Tesomet is a novel, potentially first-in-class, once-daily oral investigational therapy for hypothalamic obesity (HO) and Prader-Willi syndrome (PWS). Saniona is actively exploring worldwide partnerships that could provide immediate nondilutive income and advance Tesomet's development.
Tesomet is a fixed-dose combination of tesofensine and metoprolol. Tesofensine is a presynaptic reuptake inhibitor with appetite-suppressing properties, while metoprolol is a cardio-selective β1 receptor blocker approved since 1978 for cardiovascular conditions.
Following discussions, the FDA confirmed that Tesomet may proceed via the 505(b)(2) regulatory pathway for both HO and PWS and has granted orphan drug designation for both indications. Saniona believes the initial Phase 2 data support further development.
Hypothalamic Obesity (HO)
HO is a rare neuroendocrine disorder, most caused by hypothalamic damage following the removal of a craniopharyngioma (CP), a rare, non-cancerous central nervous system tumor. HO affects an estimated 25,000 people in the U.S. and 40,000 in Europe. There are currently no FDA-approved treatments or cures for this condition.
Saniona has completed a Phase 2 clinical trial of Tesomet for HO, a 24-week, randomized, double-blind, placebocontrolled study conducted at a single center, with an optional 24-week open-label extension (OLE). The trial included 21 adult patients, with 13 receiving Tesomet and 8 receiving placebo in the modified intent-to-treat analysis. The primary endpoint—safety and tolerability—was achieved. Tesomet also met several secondary efficacy endpoints, demonstrating statistically significant, placebo-adjusted weight loss of 6.28% (p<0.0169) and a mean reduction in waist circumference of 5.68 cm (5.00%) after 24 weeks. In the OLE, Tesomet continued to show sustained improvements in body weight and waist circumference.
Prader-Willi Syndrome (PWS)
Prader-Willi syndrome (PWS) is a rare, complex genetic disorder and the most common genetic cause of childhood obesity worldwide. It affects an estimated 34,000 people in the U.S. and 50,000 in Europe.
Saniona has completed a Phase 2 clinical trial of Tesomet in PWS, a two-center, randomized, double-blind, placebocontrolled study. The trial included nine adults and nine adolescents who received Tesomet or placebo daily for three months, followed by two open-label three-month extensions (OLE1 and OLE2) for adolescents.
The primary endpoint was change in body weight, with secondary objectives including hyperphagia, body composition, lipids, and other metabolic parameters. Adults receiving Tesomet achieved a 5.4% reduction in body weight, a notable result in this small patient population, and a statistically significant 8.1 percentage point reduction in hyperphagia, as measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), the standard tool for assessing hyperphagia in PWS. In adolescents, an increased Tesomet dose (0.125 mg to 0.25 mg) during OLE2 led to further weight reduction and an additional decrease in hyperphagia based on HQ-CT scores.
SAN903
SAN903 successfully completed preclinical development, enabling Phase 1 clinical trials, either independently or with a partner.
SAN903 is a novel, potentially first-in-class treatment for inflammatory bowel diseases (IBD), targeting both intestinal inflammation and fibrosis through inhibition of the calcium-activated potassium ion channel KCa3.1. This channel regulates immune cell activation and inflammation in chronic diseases and plays a key role in fibrosis by driving excessive connective tissue production in fibroblasts, particularly myofibroblasts. Unlike current IBD treatments, SAN903 addresses fibrosis, a major unmet need that can lead to gut obstructions requiring surgery. By preventing immune cell and fibroblast activation, SAN903 reduces inflammation, impedes cytokine release, and limits collagen secretion, potentially offering a more comprehensive treatment approach.
R&D Ion Channel Pipeline
Saniona's earlier stage discovery and development efforts are focused on the validated drug class of ion channels, which have been implicated in the pathophysiology of many disease settings and include many successful drugs such as Norvasc (amlodipine), Xylocaine (lidocaine) and Valium (diazepam). The company's ion channel drug discovery engine combines in-house expertise in chemistry, precision biology, in vivo stability/distribution, target engagement, in vivo pharmacology, and computational chemistry to accelerate the discovery of highly selective, subtype-specific, and statedependent ion channel modulators.
The core of this engine is Saniona's proprietary IONBASE database, which contains structure-activity data for more than 130,000 compounds. Of these, more than 25,000 are the company's proprietary compounds, generated over 20 years and enriched for properties conferring optimal ion channel modulation.
As a result of Saniona's ion channel drug discovery engine the company has generated a robust pipeline of orally available, potent, highly selective and differentiated ion channel modulators, including ACP-711, SAN903, SAN2219, SAN2355 and SAN2465. Saniona anticipates that this robust discovery engine will continue to generate multiple new drug candidates to add to the Saniona pipeline.
PARTNERSHIPS AND SPINOUTS
Leveraging Saniona's expertise in the field of ion channel drug discovery and the company's proprietary focused compound library and robust database (IONBASE), Saniona is continuously advancing its research programs to identify and advance additional selective ion channel clinical candidates in a range of therapeutic areas, including neurological and psychiatric disorders. Saniona's industry-leading research has formed the basis of many successful spinouts, partnerships, and licensing agreements with pharmaceutical companies internationally, such as Acadia Pharmaceuticals, Boehringer Ingelheim, AstronauTx, Pfizer, Johnson & Johnson, Proximagen, Ataxion Therapeutics (later known as Cadent Therapeutics, acquired by Novartis AG), Cephagenix, Initiator Pharma, Scandion Oncology and Medix.
Financial review
Results of Operations
April – June
Revenue for the second quarter amounted to SEK 9.3 million (8.0). Revenues include amounts from Saniona's licensing and partnership agreements with Boehringer Ingelheim, AstronauTx, Cephagenix and Acadia Pharmaceuticals. Revenues in the second quarter 2024 included amounts from Saniona's licensing and partnership agreements with Boehringer Ingelheim and AstronauTx.
Operating expenses for the second quarter amounted to SEK 35.2 million (24.1). Within operating expenses, external expenses increased by SEK 5.8 million from SEK 12.4 million to SEK 18.2 million and personnel costs increased by SEK 3.8 million from SEK 8.8 million to SEK 12.6 million, due to a higher number of employees. The share of result from associate Cephagenix increased by SEK 1.5 million from SEK 0 million in Q2 2024. This item has no cash effect.
External expenses mainly consist of research and development expenses attributable to contract research organizations (CROs) and contract manufacturing organizations supporting Saniona's clinical trials. R&D expenses amounted to SEK 8.5 million (8.9).
Personnel costs, including salaries, variable compensation, social security, and other employee benefits, amounted to SEK 12.6 million (8.8). The increase in personnel costs increased due to a higher number of employees. Included in this is a non-cash share-based compensation expense (not affecting cash flow) of SEK 0.5 million (0.8).
Net income from financial items for the second quarter amounted to SEK 0.8 million (loss 6.0). This includes a fair value gain of SEK 0 million (loss 4.3) from TO 4 warrants valued with the Black & Scholes model (no cash effect), interest expenses and commitment fee to Fenja Capital of SEK 0.2 million (1.3) and SEK 0.0 million (0.1), respectively, other interest expenses SEK 0.7 million (0.8), and financial income of SEK 1.7 million (0.5). See note 8.
The Group recognized a tax income of SEK 2.9 million (2.3).
Net cash received (used) for operating activities increased by SEK 24.9 million from SEK -14.4 million to SEK 10.5 million.
The operating cash flow was primarily attributable to the operating loss of SEK 25.9 million (16.0), and changes in working capital of SEK 34.2 million (0.4).
Net cash used in investing activities was SEK 72.4 million (0). In June 2025, Saniona acquired its headquarters, and funded the acquisitions of SEK 72.2 million (DKK 49 million) from existing cash reserves.
Net cash by financing activities was SEK 110.3 million (loss 1.3). The cash expense includes repayment of lease liabilities of SEK 1.0 million (1.3), and net proceeds from TO 4 warrants of SEK 111.3 million (0).
Cash and cash equivalents for the Group amounted to SEK 308.2 million (54.4) as of June 30, 2025.
January – June
Revenue for the period amounted to SEK 19.1 million (14.1). Revenues in the period 2025 include amounts from Saniona's licensing and partnership agreements with Boehringer Ingelheim, AstronauTx, Cephagenix and Acadia Pharmaceuticals. Revenues in the period 2024 include amounts from Saniona's licensing and partnership agreements with Boehringer Ingelheim and AstronauTx.
Operating expenses for the period amounted to SEK 61.5 million (43.7). Within operating expenses, external expenses increased by SEK 8.9 million from SEK 20.3 million to SEK 29.2 million and personnel costs increased by SEK 6.4 million from SEK 17.1 million to SEK 23.5 million, due to a higher number of employees. The share of results from associate Cephagenix increased by SEK 2.6 million from SEK 0 million in the same period in 2024, with no cash effect.
External expenses mainly consist of research and development expenses attributable to contract research organizations (CROs) and contract manufacturing organizations supporting Saniona's clinical trials. R&D expenses for the period amounted to SEK 11.1 million (11.8).
Personnel costs, including salaries, variable compensation, social security, and other employee benefits, amounted to SEK 23.5 million (17.1). The increase in personnel costs increased due to a higher number of employees. Included in this is a non-cash share-based compensation expense (not affecting cash flow) of SEK 1.1 million (1.6).
Net income from financial items was SEK 34.7 million (loss 3.3), including a fair value gain of SEK 33.6 million (0.2) from TO 4 warrants valued with the Black & Scholes model (no cash effect), interest expenses and commitment fees to Fenja Capital of SEK 0.3 million (2.6) and SEK 0.0 million (0.2), respectively, other interest expenses SEK 1.4 million (1.7), and financial income of SEK 2.8 million (1.0). See note 8.
The Group recognized a tax income in the period of SEK 4.4 million (4.1).
Net cash received (used) for operating activities increased by SEK 12.5 million from SEK -33.9 million to SEK -21.4 million.
Operating cash flow was primarily attributable to the operating loss of SEK 42.4 million (29.7), income tax payable of SEK 18.2 million (0), changes in working capital of SEK 30.8 million (-7.3), non-cash adjustments of SEK 7.1 million (5.4) and net interest income of SEK 1.2 million (loss 2.3).
Net cash used in investing activities was SEK 72.7 million (0). In June 2025, Saniona acquired its headquarters, and funded the acquisitions of SEK 72.2 million (DKK 49 million) from existing cash reserves. On July 1 Saniona took over the ownership of the headquarters.
Net cash from financing activities was SEK 109.1 million (57.0). The cash expense includes repayment of lease liabilities of SEK 2.3 million (2.6), repayment of loan to Fenja Capital SEK 0 million (20), net proceeds from TO 4 warrants of SEK 111.3 million (0) and no proceeds from rights issue (79.6).
Cash and cash equivalents for the Group amounted to SEK 308.2 million (54.4) as of June 30, 2025.
January - June
Operating expenses amounted to SEK 4.7 million (4.2), consisting of other external costs of SEK 2.8 million (2.7), personnel costs of SEK 1.3 million (1.0) and other operating expenses of SEK 0.6 million (0.6).
Profit was SEK 25.2 million (loss 10.4), including financial income of SEK 28.9 million (loss 7.2). This includes fair value gain from TO 4 warrants valued with the Black & Scholes model (no cash effect) of SEK 33.6 million (0.2), interest expenses and commitment fees to Fenja Capital of SEK 0.3 million (2.6) and SEK 0 million (0.2), respectively, other interest expenses SEK 5.0 million (4.8), and interest income of SEK 0.6 million (0.2). See note 8.
Financial position, share, share capital and ownership structure
The equity ratio for the Group was 84% (7%) as of June 30, 2025, and equity for the Group was SEK 356.3 million (6.9). Cash and cash equivalents for the Group amounted to SEK 308.2 million (54.4) as of June 30, 2025. Total assets for the Group as of June 30, 2025, were SEK 421.7 million (92.5).
In June 2025, Saniona acquired its headquarters, and funded the acquisitions of SEK 72.2 million (DKK 49 million) from existing cash reserves. On July 1 Saniona took over the ownership of the headquarters.
The equity ratio for the Parent company was 98% (70%) as of June 30, 2025, and equity for the Parent company was SEK 366.9 million (243.9). Cash and cash equivalents for the parent company amounted to SEK 5.8 million (0.8) as of June 30, 2025. Total assets for the parent company as of June 30, 2025, were SEK 373.8 million (348.3).
In April 2025 Saniona announced the outcome of exercise of warrants series TO 4, corresponding to a total of SEK 111.3 million after issue costs, which corresponds to 100 percent of the total number of TO 4 warrants.
In June 2025 Saniona announced that Fenja Capital requested conversion of the remaining outstanding convertibles for SEK 6 million, whereby a total of 1,941,747 new shares was issued to Fenja Capital at a conversion price of SEK 3.90 per share. The issue of the new shares took place in July 2025.
On June 30, 2025, the company had 136,088,387 (111,238,252) shares outstanding at SEK 0.05 per share equal to a share capital of SEK 6,804,419.35 (5,561,912.60).
On June 30, 2025, the company had 13,859 (12,070) shareholders excluding holdings in life insurance and foreign custody account holders.
Personnel
As of June 30, 2025, Saniona had 29 (22) employees including 10 (10) employees with Ph.D. degrees. Of these employees, 23 (17) were engaged in research and clinical development activities and 6 (6) were engaged in general and administrative activities. Of the 29 (22) employees, 14 (12) were women.
Risk factors and risk management
All business operations involve risk. Managed risk-taking is necessary to maintain operations. Risk may be due to events in the external environment and may affect a certain industry or market. Risk may also be company specific.
Saniona is exposed to various kinds of risks that may impact on the Group's results and financial position. The risks can be divided into operational risks and financial risks. The main risks and uncertainties which Saniona is exposed to are related to drug development, the company's collaboration agreements, competition, technology development, patents, regulatory requirements, capital requirements and currencies.
A detailed description of the Group's risk factors, and risk management is included in Saniona's 2024 Annual Report. There are no major changes in the Group's risk factors and risk management in 2025.
Audit review
The interim report has not been audited or reviewed by the company's independent auditor.
Financial calendar
Interim Report Q3 November 27, 2025, at 8:00 CET Year-end report 2025 February 26, 2026, at 8:00 CET
The Board of Directors and the CEO of Saniona AB (publ) provide their assurance that the interim report provides a fair and true overview of the Parent Company's and the Group's operations, financial position, and results, and describes material risks and uncertainties faced by the Parent Company and the companies in the Group.
Glostrup, August 28, 2025 Saniona AB
John Haurum – Chairman Thomas Feldthus – CEO
Jørgen Drejer – Deputy Chairman
Anna Ljung – Board member
Carl Johan Sundberg – Board member
THE GROUP'S CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
| KSEK | Note | 2025-04-01 | 2024-04-01 | 2025-01-01 | 2024-01-01 | 2024-01-01 |
|---|---|---|---|---|---|---|
| 2025-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2024-12-31 | ||
| 1,2,3 | ||||||
| Revenue | 4 | 9,284 | 8,019 | 19,079 | 14,053 | 334,672 |
| Total operating income | 9,284 | 8,019 | 19,079 | 14,053 | 334,672 | |
| Raw materials and consumables | ||||||
| Other external costs | -1,367 | -1,254 | -2,726 | -2,603 | -5,095 | |
| Share of result of associate | 5 | -18,194 | -12,406 | -29,206 | -20,268 | -45,014 |
| Personnel costs | -1,473 | — | -2,620 | — | 2,770 | |
| Depreciation and write-downs | 6 | -12,594 | -8,768 | -23,471 | -17,146 | -37,787 |
| Total operating expenses | -1,592 -35,220 |
-1,633 -24,061 |
-3,440 -61,463 |
-3,728 -43,745 |
-7,661 -92,787 |
|
| Operating profit (loss) | -25,936 | -16,042 | -42,384 | -29,692 | 241,885 | |
| Financial income | 8 | 1,717 | 478 | 36,498 | 1,242 | 5,128 |
| Financial expenses | -958 | -6,457 | -1,766 | -4,590 | -39,992 | |
| Total financial items | 759 | -5,979 | 34,732 | -3,348 | -34,864 | |
| Profit (loss) before tax | ||||||
| -25,177 | -22,021 | -7,652 | -33,040 | 207,021 | ||
| Income tax | 7 | 2,945 | 2,286 | 4,370 | 4,067 | -18,315 |
| Profit (loss) for the period* | -22,232 | -19,735 | -3,282 | -28,973 | 188,706 | |
| Other comprehensive income (loss) | ||||||
| for the period | ||||||
| Item that may be reclassified to profit and | ||||||
| loss | ||||||
| Translation differences | 696 | -1,386 | -7,931 | 806 | 2,851 | |
| Total other comprehensive income for the | 696 | -1,386 | -7,931 | 806 | 2,851 | |
| period, net after tax | ||||||
| Total comprehensive profit (loss)** | ||||||
| -21,536 | -21,121 | -11,213 | -28,167 | 191,557 | ||
| Profit (loss) per share, SEK | -0.17 | -0.18 | -0.03 | -0.26 | 1.77 | |
| Diluted profit (loss) per share, SEK | -0.17 | -0.18 | -0.03 | -0.26 | 1.76 |
Condensed consolidated interim statement of comprehensive income – Group
* 100% of profit (loss) for the period is attributable to Parent Company shareholders
** 100% of Total comprehensive profit (loss) the period is attributable to Parent Company shareholders
Condensed consolidated interim statement of financial position – Group
| KSEK | Note | 2025-06-30 | 2024-06-30 | 2024-12-31 |
|---|---|---|---|---|
| ASSETS | ||||
| Intangible assets | 4,417 | 4,832 | 4,753 | |
| Property & equipment* | 9 | 75,687 | 3,493 | 2,897 |
| Right of use assets | 217 | 5,258 | 4,812 | |
| Investment in associate | 155 | 397 | 2,869 | |
| Other financial assets | 10 | 240 | 243 | 248 |
| Tax assets | 4,373 | 4,019 | — | |
| Non-current assets | 85,089 | 18,242 | 15,579 | |
| Trade receivables | 17,876 | 4,154 | 15,038 | |
| Current tax assets | 7 | — | 8,311 | — |
| Other assets | 10,548 | 7,364 | 5,858 | |
| Cash and cash equivalents | 308,235 | 54,390 | 303,258 | |
| Current assets | 336,659 | 74,219 | 324,154 | |
| Total assets | 421,748 | 92,461 | 339,733 |
* As of June 30, the carrying amount of the headquarters is SEK 73.1 million. Saniona took over the ownership of the headquarters on July 1, 2025.
Page 19
Condensed consolidated interim statement of financial position – Group (continued)
| KSEK | Note | 2025-06-30 | 2024-06-30 | 2024-12-31 |
|---|---|---|---|---|
| EQUITY AND LIABILITIES | ||||
| Share capital | 6,804 | 5,562 | 5,627 | |
| Additional paid-in capital | 994,808 | 880,863 | 884,659 | |
| Reserves | -721 | 5,165 | 7,210 | |
| Accumulated deficit | -644,555 | -884,656 | -665,678 | |
| Equity | 356,336 | 6,934 | 231,818 | |
| Loan | 8,10 | — | 39,859 | — |
| Other financial liabilities | 8,10 | — | 25,205 | — |
| Lease liabilities | 10 | — | 418 | — |
| Other liabilities | 2,410 | 2,529 | 2,622 | |
| Non-current liabilities | 2,410 | 68,011 | 2,622 | |
| Trade payables | 22,582 | 10,716 | 17,527 | |
| Loan | 8,10 | 6,000 | — | 5,408 |
| Tax liabilities | — | — | 18,425 | |
| Lease liabilities | 10 | 408 | 4,859 | 5,096 |
| Other financial liabilities | 8,10 | — | — | 57,005 |
| Other liabilities | 34,012 | 1,941 | 1,832 | |
| Current liabilities | 63,002 | 17,516 | 105,293 | |
| Total liabilities | 65,412 | 85,527 | 107,915 | |
| Total equity and liabilities | 421,748 | 92,461 | 339,733 |
Share capital Additional paid-in capital Translation reserves Accumulated deficit Shareholders' equity January 1, 2024 3,206 827,803 4,359 -857,308 -21,940 Comprehensive income Loss for the period — — — -28,973 -28,973 Other comprehensive income — — 806 — 806 Total comprehensive income (loss) — — 806 -28,973 -28,167 Transactions with owners Shares issued for cash 2,356 69,472 — — 71,828 Equity component of the convertible loan — 1,287 — — 1,287 Expenses related to capital increase — -17,699 — — -17,699 Share-based compensation — — — 1,625 1,625 Total transactions with owners 2,356 53,060 — 1,625 57,041 June 30, 2024 5,562 880,863 5,165 -884,656 6,934 July 1, 2024 5,562 880,863 5,165 -884,656 6,934 Comprehensive income Income for the period — — — 217,679 217,679 Other comprehensive income — — 2,045 — 2,045 Total comprehensive income (loss) — — 2,045 217,679 219,724 Transactions with owners Equity component of the convertible loan — -139 — — -139 Conversion of convertibles 65 3,935 — — 4,000 Share-based compensation — —— 1,299 1,299 Total transactions with owners 65 3,935 — 1,299 5,160 December 31, 2025 5,627 884,659 7,210 -665,678 231,818 January 1, 2025 5,627 884,659 7,210 -665,678 231,818 Comprehensive income Loss for the period — — — -3,282 -3,282 Other comprehensive income — — -7,931 — -7,931 Total comprehensive income — — -7,931 -3,282 -11,213 Transactions with owners Shares issued for cash 1,177 113,774 — — 114,951 Warrants TO 4 — — — 23 320 23,320 Expenses related to capital increase — -3,625 — — -3,625 Share-based compensation — — — 1,085 1,085 Total transactions with owners 1,177 110,149 — 24,405 135,731 June 30, 2025 6,804 994,808 -721 -644,555 356,336
Condensed consolidated interim statement of changes in equity – Group
Condensed consolidated interim statement of cash flows – Group
| KSEK | Note | 2025-04-01 | 2024-04-01 | 2025-01-01 | 2024-01-01 | 2024-01-01 |
|---|---|---|---|---|---|---|
| 2025-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2024-12-31 | ||
| Operating profit (loss) | -25,936 | -16,042 | -42,384 | -29,692 | 241,885 | |
| Adjustments for non-cash transactions | 1,580 | 2,463 | 7,145 | 5,352 | 7,814 | |
| Changes in working capital | 34,159 | 366 | 30,831 | -7,334 | -5,997 | |
| Cash flow from operating activities | 9,803 | -13,213 | -4,408 | -31,674 | 243,702 | |
| before financial and tax items | ||||||
| Interest income received | 1,107 | 363 | 2,202 | 892 | 1,890 | |
| Interest expenses paid | -461 | -1,549 | -957 | -3,179 | -5,899 | |
| Tax credit received/paid | — | — | -18,243 | — | 8,484 | |
| Cash flow from operating activities | 10,449 | -14,399 | -21,406 | -33,961 | 248,177 | |
| Investing activities | ||||||
| Investment in tangible assets* Cash flow from investing activities |
9 | -72,404 -72,404 |
— — |
-72,732 -72,732 |
— — |
-124 -124 |
| Financing activities | ||||||
| Repayment of loan | 8 | — | — | — | -20,000 | -51,160 |
| Proceeds from issuance of new shares | ||||||
| and warrants | 114,951 | — | 114,951 | 88,874 | 88,874 | |
| Costs related to issuance of new | ||||||
| shares | -3,625 | — | -3,625 | -9,305 | -9,445 | |
| Payment of lease liabilities | -1,013 | -1,297 | -2,266 | -2,576 | -5,014 | |
| Cash flow from financing activities | 110,313 | -1,297 | 109,060 | 56,993 | 23,255 | |
| Net increase (decrease) in cash and | 48,358 | -15,696 | 14,922 | 23,032 | 271,308 | |
| cash equivalents | ||||||
| Cash and cash equivalents at | ||||||
| beginning of period | 260,661 | 71,445 | 303,258 | 30,962 | 30,962 | |
| Exchange rate adjustments | -784 | -1,359 | -9,945 | 396 | 988 | |
| Cash and cash equivalents at end of period |
308,235 | 54,390 | 308,235 | 54,390 | 303,258 |
* In June 2025, Saniona acquired its headquarters, and funded the acquisitions of SEK 72.2 million (DKK 49.0 million) from existing cash reserves.
PARENT COMPANY'S FINANCIAL STATEMENTS
Statement of income – Parent Company
| KSEK | Note | 2025-01-01 | 2024-01-01 | 2024-01-01 |
|---|---|---|---|---|
| 2025-06-30 | 2024-06-30 | 2024-12-31 | ||
| 1,2,3 | ||||
| Other operating income | 1,029 | 1,039 | 2,108 | |
| Total operating income | 1,029 | 1,039 | 2,108 | |
| Raw materials and consumables | -19 | -21 | -46 | |
| Other external costs | -2,816 | -2,663 | -5,454 | |
| Other operating expenses | -597 | -573 | -1,119 | |
| Personnel costs | 6 | -1,285 | -958 | -2,002 |
| Total operating expenses | -4,717 | -4,215 | -8,621 | |
| Operating income (loss) | -3,688 | -3,176 | -6,513 | |
| Financial income | 8 | 34,230 | 436 | 244 |
| Financial expenses | -5,333 | -7,641 | -46,473 | |
| Total financial items | 28,897 | -7,205 | -46,229 | |
| Profit (loss) before tax | 25,209 | -10,381 | -52,742 | |
| Tax on net profit (loss) | — | — | — | |
| Profit (loss) for the period | 25,209 | -10,381 | -52,742 |
Profit (loss) for the period is the same as Comprehensive income for the period as no items are identified in Other comprehensive income for the period.
Balance Sheet – Parent Company
| KSEK | Note | 2025-06-30 | 2024-06-30 | 2024-12-31 |
|---|---|---|---|---|
| ASSETS | ||||
| Investment in subsidiaries | 348,258 | 346,590 | 347,889 | |
| Financial assets | 348,258 | 346,590 | 347,889 | |
| Non-current assets | 348,258 | 346,590 | 347,889 | |
| Receivables from group companies | 18,411 | — | — | |
| Other assets | 1,246 | 933 | 220 | |
| Current receivables | 19,657 | 933 | 220 | |
| Cash and cash equivalents | 5,847 | 823 | 7,455 | |
| Current assets | 25,504 | 1,756 | 7,675 | |
| Total assets | 373,762 | 348,346 | 355,564 | |
| EQUITY AND LIABILITIES | ||||
| Restricted equity | ||||
| Share capital | 6,804 | 5,562 | 5,627 | |
| Unrestricted equity | ||||
| Share premium reserve | 994,808 | 880,863 | 884,659 | |
| Retained earnings (accumulated deficit) | -659,892 | -632,140 | -630,840 | |
| Profit (loss) for the period | 25,209 | -10,381 | -52,742 | |
| Equity | 366,929 | 243,904 | 206,704 | |
| Loan | 8 | — | 40,819 | — |
| Other financial liabilities | 8,10 | — | 24,245 | — |
| Non-current liabilities | — | 65,064 | — | |
| Trade payables | 655 | 163 | 1,187 | |
| Loan | 8,10 | 6,000 | — | 5,408 |
| Payables to group companies | — | 39,058 | 85,095 | |
| Other financial liabilities | 8,10 | — | — | 57,005 |
| Other liabilities | 178 | 157 | 165 | |
| Current liabilities | 6,833 | 39,378 | 148,860 | |
| Total liabilities | 6,833 | 104,442 | 148,860 | |
| Total equity and liabilities | 373,762 | 348,346 | 355,564 |
Notes to the condensed consolidated interim financial statements
Note 1 General Information
Saniona AB (publ), (the 'Parent Company'), Corporate Registration Number 556962-5345, is a limited liability company registered in the municipality of Malmö in the county of Skåne, Sweden. These condensed consolidated interim financial statements comprise the Parent Company and its subsidiaries (collectively the 'Group' or 'Saniona'). The Group is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels. The legal address of the head office is Murervangen 42, DK-2600 Glostrup, Denmark. The Parent Company is listed on Nasdaq Stockholm Small Cap, and its shares are traded under the ticker SANION and the ISIN code SE0005794617.
Note 2 Basis of Accounting and Significant Accounting Policies
A. Basis of Accounting
These interim financial statements for the three and six months ended June 30, 2025, have been prepared in accordance with IAS 34 Interim Financial Reporting, the Annual Accounts Act, and the Financial Reporting Board's recommendation RFR 1, Supplementary Accounting Rules for Groups. The interim financial statements for the Parent Company are prepared under the requirements of chapter 9 of the Swedish Accounting Act (1995:1554). These condensed consolidated interim financial statements should be read in conjunction with the Group's last annual consolidated financial statements as at and for the year ended December 31, 2024 ('last annual financial statements'). They do not include all the information required for a complete set of financial statements prepared in accordance with IFRS Standards. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual financial statements.
The interim financial statements have been prepared on a going concern basis. As of June 30, 2025, the Group's current assets exceed current liabilities by SEK 273,7 million. Current assets include cash and cash equivalents of SEK 308.2 million.
These financial statements were authorized for issue by the Parent Company's Board of Directors (the 'Board') on August 28, 2025.
B. Significant Accounting Policies
The Group has consistently applied the accounting policies described in the last annual financial statements to all periods presented in these condensed consolidated interim financial statements.
i. Adoption of new or revised standards
No new or changed accounting standards that came into effect on January 1, 2025, had a material impact on Saniona.
Note 3 Critical accounting judgments and key sources of estimation uncertainty
No significant changes have taken place.
Critical assessments with a significant impact on reported amounts for financial instruments are made in connection with determining the fair value of financial instruments.
The assessments include the following:
- Selection of valuation methods.
- Calculation of fair value adjustments to account for relevant risk factors.
- Assessment of which market parameters that can be observed.
Information regarding the reported value and fair value of all financial instruments appears in note 10.
We refer to accounting judgments and estimate in the 2024 Annual report.
The Group's revenue-generating activities are those described in the last annual financial statements. In the three- and six- months periods ended June 30, 2025, revenue for the Group was distributed as follows:
| Category | |||||
|---|---|---|---|---|---|
| KSEK | 2025-04-01 | 2024-04-01 | 2025-01-01 | 2024-01-01 | 2024-01-01 |
| 2025-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2024-12-31 | |
| Research and development services (bundle, over time) | 9,284 | 8,019 | 19,079 | 14,053 | 28,733 |
| License agreements (other event-based payments) | — | — | — | — | 305,939 |
| Total | 9,284 | 8,019 | 19,079 | 14,053 | 334,672 |
Geographical markets based on customer
| KSEK | 2025-04-01 | 2024-04-01 | 2025-01-01 | 2024-01-01 | 2024-01-01 |
|---|---|---|---|---|---|
| 2025-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2024-12-31 | |
| Sweden | — | — | — | — | — |
| USA | 585 | — | 1,331 | — | 300,183 |
| Germany | 2,990 | 3,626 | 6,005 | 5,673 | 17,685 |
| Denmark | 3,017 | — | 5,789 | — | 555 |
| United Kingdom | 2,692 | 4,393 | 5,954 | 8,380 | 16,249 |
| Total | 9,284 | 8,019 | 19,079 | 14,053 | 334,672 |
Note 5 External Research & Development expenses
| KSEK | 2025-04-01 | 2024-04-01 | 2025-01-01 | 2024-01-01 | 2024-01-01 |
|---|---|---|---|---|---|
| 2025-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2024-12-31 | |
| ACP-711 | — | 4,310 | — | 5,005 | 5,184 |
| SAN2355 | 5,958 | 2,303 | 8,023 | 2,635 | 5,007 |
| SAN903 | 17 | 242 | 47 | 331 | 366 |
| SAN2465 | 616 | — | 736 | — | — |
| Tesomet | 164 | 92 | 297 | 505 | 1,214 |
| Other programs | 1,760 | 1,930 | 1,956 | 3,296 | 6,456 |
| Total | 8,515 | 8,877 | 11,059 | 11,772 | 18,227 |
Note 6 Share-based payments
A. Description of share-based payment arrangements
A detailed description of the Group's share-based payment arrangements as of June 30, 2025, is provided in the most recent annual financial statements.
B. Measurement of fair values and compensation expense
April – June 2025
Share-based compensation expenses for the period totaled SEK 0.5 million (0.8).
January – June 2025
Share-based compensation expenses for the period totaled SEK 1.1 million (1.6).
The fair value of the service that entitles an employee and board member to allotment of options under Saniona's option programs is recognized as a personnel cost, with a corresponding increase in equity. Such compensation expenses represent the fair market values of warrants granted and do not represent actual cash expenditures.
The inputs used to measure fair value at the grant date based on the Black-Scholes formula, along with the reconciliation of options outstanding, are as follows:
| Incentive program | 2020:1 | 2020:2 | 2021:1 | 2022:1 |
|---|---|---|---|---|
| Options outstanding, January 1 | 355,156 | 733,900 | 700 | 2,129,821 |
| Granted during the year Forfeited during the year |
— — |
— -11,200 |
— — |
— — |
| Options outstanding, June 30 | 355,156 | 722,700 | 700 | 2,129,821 |
| Maximum number of shares to be issued |
362,259 | 729,927 | 707 | 2,151,119 |
| Grant Date Fair Value* (SEK) | 12.26 | 13.13 | 10.75 | 1.59 |
| Share Price at Grant Date* (SEK) | 28.10 | 23.50 | 19.31 | 4.24 |
| Exercise Price* (SEK) | 29.36 | 24.12 | 19.38 | 5.89 |
| Expected volatility* | 58.66% | 63.64% | 62.56% | 57.65% |
| Estimated life (years)* | 4.20 | 6.10 | 6.11 | 4.17 |
| Expected dividends* | 0 | 0 | 0 | 0 |
| Risk-free rate* | -0.2280% | -0.2772% | -0.2046% | 2.0670% |
| Remaining contractual life (years)* | 0.50 | 5.33 | 5.75 | 3.51 |
| Incentive program | 2023:1 | 2024:1 | Total | |
| Options outstanding, January 1 | 696,667 | 2,970,000 | 6,886,244 | |
| Granted during the year | — | — | — | |
| Forfeited during the year | — | — | -11,200 | |
| Options outstanding, June 30 | 696,667 | 2,970,000 | 6,875,044 | |
| Maximum number of shares to be issued |
703,633 | 2,970,000 | 6,917,645 | |
| Grant Date Fair Value* (SEK) | 5.83 | 0.57 | ||
| Share Price at Grant Date* (SEK) | 7.8 | 1.84 | ||
| Exercise Price*(SEK) | 8.84 | 4.04 | ||
| Expected volatility* | 64.39% | 54.7% | ||
| Estimated life (years)* | 3.71 | 5.55 | ||
| Expected dividends Risk-free rate |
0 1.6813% |
0 2.199% |
||
| Remaining contractual life (years) | 3.51 | 4.51 | ||
* Weighted average
As of June 30, 2025, the company had 6,875,044 options outstanding entitling the subscription of up to 6,917,645 new shares representing a dilution of 4.8 percent, based on the 136,088,387 shared issued as of June 30, 2025.
Note 7 Income tax
April – June 2025
In the second quarter, the Group recognized a non-current tax benefit of SEK 2.9 million (2.3). The tax benefit is on net loss recognized in Saniona A/S under the Danish 'Skattekreditordningen' (the 'Tax Credit Scheme').
January – June 2025
In the period, the Group recognized a non-current tax benefit of SEK 4.4 million (4.1). The tax benefit is on net loss recognized in Saniona A/S under the Danish 'Skattekreditordningen' (the 'Tax Credit Scheme').
Under the Danish Tax Credit Scheme, loss-making companies can claim payment of the tax base of the portion of their loss which is attributable to certain research and development ('R&D') activities. Companies may obtain payment of the tax base of losses originating from R&D expenses of up to DKK 25.0 million (approx. SEK 37.3 million).
Note 8 Loan and other financial liabilities
A. Fenja Capital Loan
In December 2023, Saniona announced, in connection with the Rights Issue, a renegotiation of the outstanding loan, which came into effect as of February 15, 2024. The part related to the convertibles has been divided into a liability component amounting to SEK 8.7 million and an equity component (the conversion option) amounting to SEK 1.3 million as of February 15, 2024. The liability portion is measured on an amortised cost basis and will accrue with an interest that have no cash effect.
As of June 30, 2025, the total liabilities to Fenja Capital were SEK 6.0 million as convertibles. The convertibles shall accrue at an annual interest of STIBOR 3M plus an interest margin of eight (8) per cent, and the interest shall be paid in cash by the end of each calendar quarter. The loan mature on July 31, 2025. Fenja Capital has the right to request conversion of the Convertibles into shares at a conversion price of SEK 3.09 per share, which corresponds to 150 per cent of the subscription price per share in the Rights Issue. Payment for the Convertibles will be made by offsetting Fenja Capital's claims under the existing outstanding loan.
In June 2025 Saniona announced that Fenja Capital requested conversion of the remaining outstanding convertibles for SEK 6 million, whereby a total of 1,941,747 new shares was issued to Fenja Capital at a conversion price of SEK 3.90 per share. The issue of the new shares took place in July 2025.
B. Other financial liabilities - TO 4 warrants
In February 2024, 23,555,637 TO 4 warrants were issued in connection with the rights issue.
Due to the variable components in the calculation of the value of the TO 4 warrants, this will be calculated at each reporting period. The value of the TO 4 warrants was SEK 23.3 million at the exercise of the warrant's series TO 4, which was reported under the Equity.
In April 2025, Saniona announced the outcome of exercise of warrants series TO 4, corresponding to a total of SEK 111.3 million after issue costs, which corresponds to 100 percent of the total number of TO 4 warrants.
Note 9 Property & equipment
In June 2025, Saniona acquired its headquarters, and has funded the acquisitions of SEK 72.2 million (DKK 49million) from existing cash reserves. As of June 30, the carrying amount of the headquarters is SEK 73.1 million, and equipment is SEK 2.6 million. Saniona took over the ownership of the headquarters on July 1, 2025.
Note 10 Financial instruments – fair values
A. Accounting classifications and fair values
The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value when the carrying amount is a reasonable approximation of fair value.
| June 30, 2025 |
Carrying amount | Fair value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| KSEK | Note | Financial assets at amortized cost |
Mandatorily at FVTPL - others |
Financial liabilities at amortized cost |
Total | Level 1 | Level 2 | Level 3 | Total |
| Financial assets measured at fair value | Financial | ||||||||
| Contingent consideration receivable | assets at — |
240 | — | 240 | — | — | 240 | 240 | |
| amortized — |
240 | — | 240 | — | — | 240 | 240 | ||
| Financial assets not measured at fair value | cost | ||||||||
| Trade receivables | 17,876 | — | — | 17,876 | — | — | — | — | |
| Other current financial assets | 4,827 | — | — | 4,827 | — | — | — | — | |
| Cash and cash equivalents | 308,235 | — | — | 308,235 | — | — | — | — | |
| 330,938 | — | — | 330,938 | — | — | — | — | ||
| Financial liabilities not measured at fair value | |||||||||
| Trade payables | — | — | 22,582 | 22,582 | — | — | — | — | |
| Fenja Capital Loan | 8 | — | — | 6,000 | 6,000 | — | — | — | — |
| Lease liabilities | — | — | 408 | 408 | — | — | — | — | |
| — | — | 28,990 | 28,990 | — | — | — | — |
INTERIM REPORT FOR SANIONA AB (PUBL)
January – June 2025
| Page 31 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| December 31, 2024 |
Carrying amount | Fair value | |||||||
| KSEK | Note | Financial assets at amortized cost |
Mandatorily at FVTPL - others |
Financial liabilities at amortized cost |
Total | Level 1 | Level 2 | Level 3 | Total |
| Financial assets measured at fair value | Financial | ||||||||
| Contingent consideration receivable | assets at — |
248 | — | 248 | — | — | 248 | 248 | |
| amortized — |
248 | — | 248 | — | — | 248 | 248 | ||
| Financial assets not measured at fair value | cost | ||||||||
| Trade receivables | 15,038 | — | — | 15,038 | — | — | — | — | |
| Other current financial assets | 4,844 | — | — | 4,844 | — | — | — | — | |
| Cash and cash equivalents | 303,258 | — | — | 303,258 | — | — | — | — | |
| 323,140 | — | — | 323,140 | — | — | — | — | ||
| Financial liabilities measured at fair value | |||||||||
| Other financial liabilities* | 8 | — | 57,005 | — | 57,005 | — | 57,005 | — | 57,005 |
| — | 57,005 | — | 57,005 | — | 57,005 | — | 57,005 | ||
| Financial liabilities not measured at fair value | |||||||||
| Trade payables | — | — | 17,477 | 17,477 | — | — | — | — | |
| Fenja Capital Loan |
8 | — | — | 5,408 | 5,408 | — | — | — | — |
| Lease liabilities | — | — | 5,096 | 5,096 | — | — | — | — | |
| — | — | 27,981 | 27,981 | — | — | — | — |
* The TO 4 warrants are valued using the Black & Scholes model applied with the necessary variables.
B. Measurement of fair values
i. Valuation techniques and significant unobservable inputs
The contingent consideration receivable from Novartis as of December 31, 2021, has been measured using a probability-weighted discounted cash flow valuation technique, which considers the present value of expected payments, discounted using a risk-adjusted discount rate. As of June 30, 2025, the contingent consideration has been measured at SEK 0.2 million.
ii. Transfers
During the three and six months ended June 30, 2025, and 2024, there were no transfers of financial instruments between the different valuation hierarchy categories.
iii. Reconciliation of Level 3 fair values
The following table shows a reconciliation from the opening balances to the closing balances for Level 3 fair values.
| KSEK | Contingent consideration |
|---|---|
| Balance, January 1, 2025 | 248 |
| Cash received | — |
| Changes in Fair Value | — |
| Foreign currency (included in 'net gains/losses on financial items') | -8 |
| Balance, June 30, 2025 |
240 |
Page 33
Note 11 Alternative Performance Measures
Saniona presents certain financial measures in the interim report that are not defined according to International Financial Reporting Standards (IFRS), so called alternative performance measures. These have been noted with an "*" in the tables below. The company believes that these measures provide valuable supplementary information for investors and company management as they enable an assessment of relevant trends of the company's performance. These financial measures should not be regarded as substitutes for measures defined per IFRS. Since not all companies calculate financial measures in the same way, these are not always comparable to measures used by other companies.
| Key figure | Definition | Relevance |
|---|---|---|
| Operating profit/loss | Profit/loss before financial items and tax. |
The operating profit/loss is used to measure the profit/loss generated by the operating activities. |
| Operating margin | Operating profit/loss as a proportion of revenue. |
The operating margin shows the proportion of revenue that remains as profit before financial items and taxes and has been included to allow investors to get an impression of the company's profitability. |
| Liquidity ratio | Current assets divided by current liabilities. |
Liquidity ratio has been included to show the Company's short-term payment ability. |
| Equity ratio | Shareholders' equity as a proportion of total assets. |
The equity ratio shows the proportion of total assets covered by equity and provides an indication of the company's financial stability and ability to survive in the long term. |
| Equity per share | Equity divided by the shares outstanding at the end of the period. |
Equity per share has been included to provide investors with information about the equity reported in the balance sheet as represented by one share. |
| Cash flow per share | Cash flow for the period divided by the average shares outstanding for the period. |
Cash flow per share has been included to provide investors with information about the cash flow represented by one share during the period. |
The definition and relevance of key figures not calculated according to IFRS are listed in the table below.
Financial key figures
| 2025-04-01 | 2024-04-01 | 2025-01-01 | 2024-01-01 | 2024-01-01 | |
|---|---|---|---|---|---|
| 2025-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2024-12-31 | |
| Revenue, KSEK | 9,284 | 8,019 | 19,079 | 14,053 | 334,672 |
| Total operating expenses, KSEK | -35,220 | -24,061 | -61,463 | -43,745 | -92,787 |
| Operating profit (loss), KSEK* | -25,936 | -16,042 | -42,384 | -29,692 | 241,885 |
| Cash flow for the period, KSEK | 48,358 | -15,696 | 14,922 | 23,032 | 271,308 |
| Average shares outstanding | 131,654,693 | 111,238,252 | 122,146,545 | 101,227,376 | 106,391,031 |
| Diluted average shares outstanding | 125,176,316 | 111,238,252 | 121,843,615 | 101,227,376 | 107,050,372 |
| Shares outstanding at the end of the period | 136,088,387 | 111,238,252 | 136,088,387 | 111,238,252 | 112,532,750 |
| Average number of employees | 27 | 23 | 25 | 23 | 22 |
| Operating margin* | |||||
| Operating profit (loss), KSEK | -25,936 | -16,042 | -42,384 | -29,692 | 241,885 |
| Revenue, KSEK | 9,284 | 8,019 | 19,079 | 14,053 | 334,672 |
| Operating margin, % | -279% | -200% | -222% | -211% | 72% |
| Cash flow per share* | |||||
| Cash flow for the period, KSEK | 48,358 | -15,696 | 14,922 | 23,032 | 271,308 |
| Averages number of shares outstanding at | 131,654,693 | 111,238,252 | 122,146,545 | 111,238,252 | 106,391,031 |
| the end of the period Cash flow per share, SEK |
0.37 | -0.14 | 0.12 | 0.23 | 2.55 |
| Earnings per share | |||||
| Profit (loss) for the period, KSEK | -22,232 | -19,735 | -3,282 | -28,973 | 188,706 |
| Average shares outstanding during the | 131,654,693 | 111,238,252 | 122,146,545 | 101,227,376 | 106,391,031 |
| period | |||||
| Earnings per share, SEK Diluted earnings per share, SEK |
-0.17 -0.17 |
-0.18 -0.18 |
-0.03 -0.03 |
-0.29 -0.29 |
1.77 1.76 |
| 2025-06-30 | 2024-06-30 | 2024-12-31 | |||
| Cash and cash equivalent, KSEK | 308,235 | 54,390 | 303,258 | ||
| Equity, KSEK | 356,336 | 6,934 | 231,818 | ||
| Total Equity and liabilities, KSEK | 421,748 | 92,461 | 339,733 | ||
| Equity per share* | |||||
| Equity, KSEK | 356,336 | 6,934 | 231,818 | ||
| Shares outstanding at the end of the period | 136,088,387 | 111,238,252 | 112,532,750 | ||
| Equity per share, SEK | 2.62 | 0.06 | 2.06 | ||
| Equity ratio* | |||||
| Equity, KSEK | 356,336 | 6,934 | 231,818 | ||
| Total assets, KSEK | 421,748 | 92,461 | 339,733 | ||
| Equity ratio, % | 84% | 7% | 68% | ||
| Liquidity ratio* | |||||
| Current assets, KSEK | 336 659 | 74,219 | 324,154 | ||
| Current liabilities, KSEK | 63,002 | 17,516 | 105,293 | ||
| Liquidity ratio, % | 534% | 424% | 308% |
* = Alternative performance measures
Note 12 Related parties
The Group had a Consultancy Agreement with the former board member Pierandrea Muglia, for the provision of advisory services regarding Saniona's research and development. The agreement was terminated on March 1, 2025, where Saniona appointed Pierandrea Muglia as CMO. In the period January until February 28, 2025, the fee for Pierandrea's services was SEK 0.4 million (January until June 30, 2024 - SEK 0.6 million).
The Group had a Consultancy Agreement with Chairman of the board John Haurum, for the provision of advisory services regarding Saniona's Business Development. The agreement was terminated end of May 2025, after John Haurum was elected as Chairman of the board. In the period January until May 31, 2025, the fee for John's services was SEK 60 thousand (0).
The Group has a Consultancy Agreement with ordinary board member, Jørgen Drejer, for the provision of advisory services regarding Saniona's research and development, business development and financing effort. In the period January until June 2025, the fee for Jørgen's services was SEK 12 thousand (243).
Note 13 Subsequent Events to the Balance Sheet Date
• On August 20, Saniona announced Licensing Agreement with Jazz Pharmaceuticals for SAN2355 in epilepsy and other potential indications. Saniona will receive USD 42.5 million in upfront payment.
This information is information that Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-28 08:00 CEST.
Saniona AB Murervangen 42 DK-2600 Glostrup Denmark www.saniona.com
